secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009641
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M
------------------------------------------------------------------------------

- Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.
- Reaffirms FY2024 guidance: net product revenue $55-60M, SG&A $39-42M, R&D $8-10M.
- Hosts Feb 5, 2025 conference call to update commercial launch plan for Emrosi (minocycline HCl ER 40 mg).
- Investor presentation (Exhibit 99.1) attached but specific slide content not disclosed in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/0001104659-25-009641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/tm255603d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer